Skip to main content

Table 1 Psychiatric adverse effects in DAAs

From: Psychiatric treatment considerations with direct acting antivirals in hepatitis C

  

Telaprevir trials

  

Boceprevir trials

 
 

ADVANCE [[4]]

ILLUMINATE* [[31]]

REALIZE [[32]]

SPRINT-1 [[33]]

SPRINT-2 [[5]]

RESPOND-2 [[34]]

Psychiatric side effect

      

Fatigue

57% (57%)

68%

55% (40%)

68% (55%)

53% (60%)

54% (50%)

Insomnia

32% (31%)

31%

26% (26%)

28% (38%)

33% (32%)

30% (20%)

Irritability

22% (18%)

-

14% (16%)

-

22% (24%)

19% (13%)

Depression

18% (22%)

-

9% (14%)

-

23% (22%)

12% (15%)

Anxiety

10% (12%)

-

-

-

-

-

  1. % - percent for study arm corresponding to current standard of care for DAA.
  2. (%) – percent for pegylated IFNα and Ribavirin treatment arm.
  3. *ILLUMINATE – did not have pegylated IFNα and Ribavirin treatment arm.
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us